202 related articles for article (PubMed ID: 27100888)
1. IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.
Le TT; Skak K; Schroder K; Schroder WA; Boyle GM; Pierce CJ; Suhrbier A
PLoS One; 2016; 11(4):e0153975. PubMed ID: 27100888
[TBL] [Abstract][Full Text] [Related]
2. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
3. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization.
Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072
[TBL] [Abstract][Full Text] [Related]
4. Analysis of apoptosis-associated molecules Erythroid differentiation regulator 1, bcl-2 and p53 in actinic keratosis after treatment with ingenol mebutate.
Woo YR; Lim JH; Jeong SW; Cho DH; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1012-1017. PubMed ID: 28370377
[TBL] [Abstract][Full Text] [Related]
5. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
6. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
Berman B; Nestor MS; Newburger J; Park H; Swenson N
J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
[TBL] [Abstract][Full Text] [Related]
7. Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer.
Liang X; Grue-Sørensen G; Månsson K; Vedsø P; Soor A; Stahlhut M; Bertelsen M; Engell KM; Högberg T
Bioorg Med Chem Lett; 2013 Oct; 23(20):5624-9. PubMed ID: 23993332
[TBL] [Abstract][Full Text] [Related]
8. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
9. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches.
Cozzi SJ; Ogbourne SM; James C; Rebel HG; de Gruijl FR; Ferguson B; Gardner J; Lee TT; Larcher T; Suhrbier A
J Invest Dermatol; 2012 Apr; 132(4):1263-71. PubMed ID: 22189786
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
11. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma.
García-de-la-Fuente MR; Santacana M; Verdaguer J; Vilardell F; Garí E; Casanova JM
Australas J Dermatol; 2020 May; 61(2):e200-e207. PubMed ID: 31944277
[TBL] [Abstract][Full Text] [Related]
15. Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2.
Freiberger SN; Cheng PF; Iotzova-Weiss G; Neu J; Liu Q; Dziunycz P; Zibert JR; Dummer R; Skak K; Levesque MP; Hofbauer GF
Mol Cancer Ther; 2015 Sep; 14(9):2132-42. PubMed ID: 26116359
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice.
Cozzi SJ; Le TT; Ogbourne SM; James C; Suhrbier A
Arch Dermatol Res; 2013 Jan; 305(1):79-83. PubMed ID: 22871992
[TBL] [Abstract][Full Text] [Related]
17. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
19. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.
Emmert S; Haenssle HA; Zibert JR; Schön M; Hald A; Hansen MH; Litman T; Schön MP
PLoS One; 2016; 11(9):e0160096. PubMed ID: 27612149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
